Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecentriq in advanced NSCLC after PD-1 therapy
NCT03014648Phase 2Completed
- Start
- Jul 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC). Started Jul 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03014648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014648.